

Edgar Filing: HAEMONETICS CORP - Form 8-K

HAEMONETICS CORP  
Form 8-K  
June 18, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549  
FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

June 18, 2002  
Date of Report (Date of Earliest Event Reported)

HAEMONETICS CORPORATION  
(Exact Name of Registrant as Specified in its Charter)

Massachusetts -----	1-10730 -----	04-2882273 -----
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification Number)
400 Wood Road, Braintree, Massachusetts		02184-9114
(Address of principal executive offices)		(zip code)
	(781) 848-7100	
	(Registrant's telephone number, including area code)	

ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT  
-----

Haemonetics Corporation ("Haemonetics") terminated the engagement of Arthur Andersen LLP ("Andersen") as Haemonetics' independent public accountants on June 18, 2002. This decision was approved by the Audit Committee of Haemonetics' Board of Directors and by the Board of Directors. Andersen's report on Haemonetics' financial statements for the fiscal years ended March 31, 2001 and March 30, 2002 did not contain an adverse opinion, disclaimer of opinion or any qualifications or modifications related to uncertainty, limitation of audit scope or application of accounting principles. During the fiscal years ended March 31, 2001 and March 30, 2002 and through the date of termination of the engagement, there were no disagreements with Andersen on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure with respect to Haemonetics' financial statements that, if not resolved to Andersen's satisfaction, would have caused Andersen to make reference to the subject matter of the disagreement in connection with Andersen's reports.

During the fiscal years ended March 31, 2001 and March 30, 2002 and through the date of termination of the engagement, there have been no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K promulgated by the Securities and Exchange Commission (the "Commission").

Haemonetics has requested that Andersen furnish it with a letter addressed to the Commission stating whether or not it agrees with the above statements. Such letter is filed as Exhibit 16.1 hereto.

On June 18, 2002 Haemonetics engaged Ernst & Young LLP ("E&Y") as its

